Research Article

The Utility of Perirenal Fat in Determining the Risk of Onset and Progression of Diabetic Kidney Disease

Table 3

The baseline characteristics of patients with L-PFT and H-PFT in the follow-up study.

L-PFT (n = 41)H-PFT (n = 177)

Gender (M/F)21/20122/550.032
Age (years)19 (53–68)57 (48–66)0.140
Diabetes course (years)4 (1–10)5 (1–14)0.214
Hypertension (n, %)25, 61.0102, 57.6<0.001
BMI (kg/m2)23.70 (20.70–28.65)24.41 (21.52–27.37)0.581
HbA1C (%)9.50 (7.35–11.00)8.30 (6.90–10.40)0.110
FPG (mmol/L)8.41 (6.16–12.62)7.94 (5.99–10.88)0.544
UACR (mg/g)13.80 (9.53–21.48)17.04 (12.58–21.01)0.184
UTP (g/24 h)0.07 ± 0.040.08 ± 0.020.561
ALB (g/L)39.90 (37.25–42.60)40.50 (37.65–44.15)0.362
Urea (mmol/L)5.86 (4.56–6.95)5.90 (4.66–7.00)0.401
SCr (μmol/L)70.00 (53.6–95.2)72.00 (55.0–105.5)0.412
UA (μmol/L)334.66 ± 112.35338.30 ± 129.230.868
Tch (mmol/L)3.35 (2.03–4.62)3.92 (2.22–5.22)0.103
TG (mmol/L)2.28 (1.09–4.07)2.53 (1.48–4.29)0.247
HDL (mmol/L)1.06 (0.83–1.26)1.01 (0.85–1.28)0.897
LDL (mmol/L)2.27 (1.95–3.09)2.63 (2.04–3.17)0.338
eGFR (mL/min/1.73 m2)104.40 (80.0–112.5)105.34 (86.6–113.9)0.630
Rx
 None (diet alone) (n, %)3 (8.0)15 (8.3)0.285
 OHA (n, %)8 (19.8)37 (21.0)0.345
 Insulin ± OHA (n, %)24 (58.5)102 (57.5)0.114
 Antihypertensive drugs (n, %)15 (36.2)63 (35.4)0.186
 ACE-I/ARBs (n, %)9 (22.1)38 (21.5)0.201
 Hypolipidemic therapy (n, %)14 (34.0)59 (33.5)0.215
PFT (cm)0.73 ± 0.151.34 ± 0.31<0.001

L-PFT: lower PFT group; H-PFT: higher PFT group; BMI: body mass index; hypertension: proportion of patients with hypertension; HbA1C: glycated hemoglobin ratio; FPG: fasting plasma glucose; UTP: total 24-hour urinary protein; UACR: urinary creatinine protein ratio; ALB: serum albumin; urea: serum urea nitrogen; SCr: blood creatinine; UA: blood uric acid; Tch: total serum cholesterol; TG: triglycerides; HDL: serum high-density lipoprotein; LDL: serum low-density lipoprotein; eGFR: predicted glomerular filtration rate; PFT: perirenal fat thickness; OHA: oral hypoglycemic agent; Rx: prescription.